W
Wendy Cheng
Researcher at Royal Perth Hospital
Publications - 90
Citations - 2838
Wendy Cheng is an academic researcher from Royal Perth Hospital. The author has contributed to research in topics: Hepatitis C & Hepatitis C virus. The author has an hindex of 28, co-authored 83 publications receiving 2524 citations. Previous affiliations of Wendy Cheng include University of Queensland & University of Western Australia.
Papers
More filters
Journal ArticleDOI
Enzyme-Linked Immunosorbent Assay for Campylobacter pyloridis: Correlation with Presence of C. pyloridis in the Gastric Mucosa
C S Goodwin,E D Blincow,G Peterson,C. R. Sanderson,Wendy Cheng,Barry J. Marshall,J R Warren,R McCulloch +7 more
TL;DR: Antibody to Campylobacter pyloridis was measured by ELISA in the sera of 160 patients from whom gastric biopsy specimens were also obtained, and Histological diagnosis of active chronic gastritis was associated with a high median ELISA titer (485 E), chronic gast arthritis with a much lower titer(150 EU), and normal histology with a titer of 110 EU.
Journal ArticleDOI
The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection
E.J. Gane,Young-Suk Lim,Stuart C. Gordon,Kumar Visvanathan,Eric Sicard,Richard N. Fedorak,Stuart K. Roberts,Benedetta Massetto,Zhishen Ye,Stefan Pflanz,Kimberly L. Garrison,Anuj Gaggar,G. Mani Subramanian,John G. McHutchison,Shyamasundaran Kottilil,B. Freilich,Carla S. Coffin,Wendy Cheng,Yoon Jun Kim +18 more
TL;DR: Oral GS-9620 was safe, well tolerated, and associated with induction of peripheral ISG15 production in the absence of significant systemic IFN-alpha levels or related symptoms in patients with chronic hepatitis B.
Journal ArticleDOI
Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.
Kosh Agarwal,Scott Fung,Tuan T. Nguyen,Wendy Cheng,Eric Sicard,Stephen D. Ryder,John F. Flaherty,Eileen Lawson,Sally Zhao,G. Mani Subramanian,John G. McHutchison,Edward Gane,Graham R. Foster +12 more
TL;DR: Tenofovir alafenamide 25 mg was safe and well tolerated; declines in HBV DNA were similar to ten ofovir disoproxil fumarate at all doses evaluated.
Journal ArticleDOI
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease
Mohammed Eslam,Ahmed M. Hashem,Reynold Leung,Manuel Romero-Gómez,Thomas Berg,Gregory J. Dore,Henry L.K Chan,William L. Irving,David Sheridan,Maria Lorena Abate,Leon A. Adams,Alessandra Mangia,Martin Weltman,Elisabetta Bugianesi,Ulrich Spengler,Olfat G. Shaker,Janett Fischer,Lindsay Mollison,Wendy Cheng,Elizabeth E. Powell,Jacob Nattermann,Stephen M. Riordan,Duncan McLeod,Nicola J. Armstrong,Mark W. Douglas,Christopher Liddle,David R. Booth,Jacob George,Golo Ahlenstiel,Javier Ampuero,Margaret Bassendine,Vincent Wai-Sun Wong,Chiara Rosso,Rose White,Lavinia Mezzabotta,Vijayaprakash Suppiah,M. Michalk,Barbara Malik,Gail V. Matthews,Tanya L. Applegate,Jason Grebely,Vincenzo Fragomeli,Julie R. Jonsson,Rosanna Santaro +43 more
TL;DR: It is demonstrated that a single-nucleotide polymorphism (rs12979860) in the intronic region of interferon-λ4 (IFNL4) is a strong predictor of fibrosis in an aetiology-independent manner and is maximal in young females, especially those with HCV genotype 3.
Journal ArticleDOI
Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy.
Silvana Gaudieri,Andri Rauch,Andri Rauch,Katja Pfafferott,Eleanor Barnes,Wendy Cheng,Geoff McCaughan,Nicholas A. Shackel,Gary P. Jeffrey,Lindsay Mollison,Ross I. Baker,Hansjakob Furrer,Huldrych F. Günthard,Elizabeth Freitas,Isla Humphreys,Paul Klenerman,Simon Mallal,Ian James,Stuart K. Roberts,David Nolan,Michaela Lucas,Michaela Lucas +21 more
TL;DR: Drug and host immune responses are likely to provide powerful selection forces that shape HCV genetic diversity and replication dynamics, and considered in terms of drug resistance as well as host “immune resistance” in the STAT‐C treatment era could provide important information toward an optimized and individualized therapy for chronic hepatitis C.